Drug Safety

From time to time, the CSEM receives notices about drug safety issues from Health Canada.

Current notices:

• Summary Safety Review — SGLT2 inhibitors: Health Canada warns of potential risks of prolonged or incident DKA despite stopping treatment (August 20, 2024)
  • English
  • Français
• Summary Safety Review — Nexavar® (sorafenib): Health Canada assessing the potential risk of tumour lysis syndrome (May 15, 2024)
  • English
  • Français
• Summary Safety Review — iodinated contrast medium: Health Canada assessing the potential risk of hypothyroidism in children under 3 years of age (May 9, 2024)
  • English
  • Français
• Taro-Zoledronic acid injection recalled because it may contain particulate matter (August 9, 2022)
  • English
  • Français
• Summary Safety Review — Nexavar® (sorafenib): Health Canada assessing the potential risk of thrombotic microangiopathy (August 10, 2022)
  • English
  • Français
• Summary Safety Review — methadone: Health Canada assessing the potential risk of hypoglycemia (February 8, 2022)
  • English
  • Français
• Lupron® and Lupron Depot®: Risk of pseudotumor cerebri/idiopathic intracranial hypertension in pediatric patients (January 4, 2022)
  • English
  • Français
• One lot of Eli Lilly Glucagon (DIN 02243297, lot D239382A, expiry May 10, 2022) recalled (September 25, 2021):
  • English
  • Français
• Dopamine agonist withdrawal syndrome (June 7, 2021):
  • English
  • Français